US › Healthcare

Regenxbio Inc (RGNX)

US · Healthcare · Biotechnology

$8.21+2.94%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$108.0M

Revenue YoY

+405.7%

Net profit

$22.7M

EPS

$0.43

EPS estimate

$0.12

Net margin

21.0%

EPS came in at 0.43 against a street estimate of 0.12 — a beat of 258.3%.

Key statistics

Market cap

$573.7M

Forward P/E

0.0

P/B

7.85

Book value

$1.32

EPS (TTM)

$-3.78

52-week high

$16.19

52-week low

$5.46

50-day MA

$10.60

200-day MA

$10.26

Beta

0.93

Analyst view

Analysts rate Regenxbio Inc a buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $23.73.

Shareholding

Insiders

6.55%

Institutions

65.60%

Largest institutional holders

Fund	Stake
BlackRock Inc	8.80%
Redmile Group, LLC	6.65%
JPMorgan Chase & Co	5.30%
State Street Corp	4.16%
Morgan Stanley - Brokerage Accounts	3.15%
Vanguard Capital Management, LLC	3.06%
The Goldman Sachs Group Inc	2.80%
Qube Research & Technologies	2.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Regenxbio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.